A surprising hyperpigmentation of the gums and tongue

Spiller, Robin
December 2008
Gut;Dec2008, Vol. 57 Issue 12, p1697
Academic Journal
The article presents the medical case of a 33-year-old caucasian women with chronic hepatitis C. It states that 42 weeks into the treatment, blackish pigmented patches showed on the dorsal and lateral surface of her tongue and diffusely on the gums. Moreover, a year after the completion of therapy, a sustained virological response was present.


Related Articles

  • Total HCV cure remains elusive. Shafer, Emily // Hem/Onc Today;10/10/2012, Vol. 13 Issue 19, p24 

    The article discusses research being done on the significant advances in the treatment of hepatitis C.

  • Optimum Duration of Treatment for Hepatitis C. Kuritzky, Louis // Internal Medicine Alert;8/29/2007, Vol. 29 Issue 16, p128 

    The article reports on the optimum duration of treatment for hepatitis C.

  • New Combination Therapy for Hepatitis C. Harrar, Sari; Matus, Jordan // Prevention;Jun2002, Vol. 54 Issue 6, p161 

    Reports on the effectiveness of enhanced interferon plus ribavirin for the treatment of hepatitis C.

  • Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature. Dag, Muhammed Sait; Öztürk, Zeynel Abidin; Yılmaz, Nimet; Çam, Hakan; Kadayıfçı, Abdurrahman // Wiener Klinische Wochenschrift;Sep2013, Vol. 125 Issue 17/18, p537 

    The Interferon (IFN) which is the standard treatment for Hepatitis C, may cause a lot of side effects including dermatological anomalies. This paper presents a psoriasis case which occurred in relation with the treatment of acute hepatitis C (AHC) with peginterferon alfa (peg-IFN-α). A...

  • The new era of hepatitis C treatment: still the tip of the iceberg? GASBARRINI, A.; PONZIANI, F. R.; ANNICHIARICO, B. E.; SICILIANO, M.; CRAXÌ, A. // European Review for Medical & Pharmacological Sciences;Sep2013, Vol. 17 Issue 17, p2271 

    The author discusses the new age of hepatitis C treatment. The revolution of hepatitis C virus (HCV) infection treatment began in the early 1990s, with the introduction of interferon (IFN) alpha, but the optimal results have been attained in the recent years. Hepatitis C, far from the...

  • Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Subramanian, G. Mani; Fiscella, Michele; Lamousé-Smith, Araba; Zeuzem, Stefan; McHutchison, John G. // Nature Biotechnology;Dec2007, Vol. 25 Issue 12, p1411 

    Treatment regimens based on the use of interferon-α (IFN-α) remain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 million people worldwide. Treatment options include unmodified IFN-α given three times weekly or pegylated IFNs given once...

  • Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. Poordad, Fred; Reddy, K. Rajender; Martin, Paul // Clinical Infectious Diseases;1/1/2008, Vol. 46 Issue 1, p78 

    Background. Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon-alfa and ribavirin—the...

  • Peginterferon-α.  // Reactions Weekly;10/13/2007, Issue 1173, p22 

    The article describes the case of an approximately 54-year-old woman who has experienced an exacerbation of her pre-existing Graves' ophthalmopathy during treatment with peginterferon-&aalpha; for chronic hepatitis C virus infection. After her upper eyelid recession, in 2005, she presented with...

  • Predicting response to hepatitis C therapy. Oh, Thomas S.; Rice, Charles M. // Journal of Clinical Investigation;Jan2009, Vol. 119 Issue 1, p5 

    Current treatment for chronic hepatitis C is expensive, is often accompanied by burdensome side effects, and, sadly, fails in almost half of cases. The ability to predict such failures prior to treatment could save a great deal of pain and expense for the patient with HCV. In this issue of the...


Read the Article


Sign out of this library

Other Topics